APLLTD vs BROOKS: Stock Comparison
Alembic Pharmaceuticals Limited is the larger company by market capitalisation. Alembic Pharmaceuticals Limited shows a higher dividend yield, faster revenue growth and a higher ROCE, while Brooks Laboratories Limited shows a lower P/E, a higher ROE and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
APLLTD leads 6; BROOKS leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | APLLTD | BROOKS |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | APLLTD | BROOKS |
|---|---|---|
| Live Price | ₹821.75 | ₹69.58 |
| Day Change | 0.94% | -3.45% |
| Volume | 35,565 | 91,999 |
| 52-Week High | ₹998 | ₹163.9 |
| 52-Week Low | ₹635.8 | ₹36.3 |
| Distance from 52W High | -17.66% | -57.55% |
Valuation
| Metric | APLLTD | BROOKS |
|---|---|---|
| Market Cap | ₹16,15,257.47 L Cr | ₹182 Cr |
| P/E Ratio | 23.3x | 8.22x |
| P/B Ratio | 2.85x | 1.65x |
| EPS | ₹35.25 | ₹7.32 |
| Book Value | ₹288.7 | ₹33.3 |
| Dividend Yield | 1.46% | 0% |
Growth
| Metric | APLLTD | BROOKS |
|---|---|---|
| Revenue Growth (TTM YoY) | 4.4% | -6.37% |
| EPS Growth (TTM YoY) | 29.2% | 0% |
| Qtr Sales Growth | 4.41% | 42.3% |
| Qtr Profit Growth | 40.8% | 498% |
Profitability & Leverage
| Metric | APLLTD | BROOKS |
|---|---|---|
| ROE | 13.4% | 20.04% |
| ROCE | 12.6% | -9.93% |
| Net Margin | 8.98% | 28.67% |
| Operating Margin | 15.2% | 7.74% |
| Debt to Equity | 0.25x | 0.06x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | APLLTD | BROOKS |
|---|---|---|
| Promoter Holding | 69.36%▲ 0.13 pp | 52.62% |
| FII Holding | 4.18%▼ 0.07 pp | 0%▼ 0.17 pp |
| DII Holding | 15.94%▼ 0.24 pp | 10.38% |
| Public Holding | 10.01%▲ 0.18 pp | 37%▲ 0.16 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Alembic Pharmaceuticals Limited and Brooks Laboratories Limited.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.